2. Shimabukuro-Vornhagen, A., et al., Cytokine release syndrome. J Immunother Cancer, 2018. 6(1): p. 56. 3. Hay, K.A., et al., Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood, 2017. 130(21): p. 2295...
但是在应用CART细胞治疗的患者所发生的发热,主要是因为大量的细胞释放因子所发生的。美国移植和细胞治疗学会(American Society for Transplantation and Cellular Therapy,ASTCT)于2018 年 6 月在华盛顿特区举办了一个研讨会,该研讨会发布了针对CRS和ICANS的ASTCT共识评分系统,目的是在CRS分级上达成共识,更好地指导CRS的...
Norlase received US FDA 510(k) clearance and announced the commercial launch of Leaf, which allows ophthalmologists to perform laser therapy in almost any exam room with minimal setup time and physical space. The entire laser unit attaches to an existing slit lamp, eliminating the need for a ...
The study aims to compare the clinical efficacy and cognitive side effect of magnetic seizure therapy (MST) and modified electroconvulsive therapy (MECT) on clozapine resistant schizophrenia (CRS). Methods Sixteen patients with CRS were enrolled in this randomized, parallel-group, controlled clinical ...
CART19 (19-28BBζ, 25,000 cells), Ramos (CD19+, 50,000 cells), and immature dendritic cells (iDC, 2,500 cells) were co-cultured in a 96 well plate for 48hrs in the presence of varying concentrations of duvelisib (0.3nM-1000nM). Secreted IL-6, a surrogate marker of CRS, was ...
CART19 combines an antiCD19 scFv antibody antigen recognition domain with intracellular signal 1 (CD3z) and signal 2 (4-1BB) domains into a single chimeric protein, which results in remarkable antitumor activity with massive in vivo expa... SA Grupp,M Kalos,DM Barrett,... - 《Cancer Resea...
and 1 grade 3 who displayed mild transient hypotension for only 1 day while there were 79.5% blast tumor cells in the bone marrow before CART therapy.Conclusions:These results suggest BCMA-CD19 bispecific CART self-inhibiting IFNG signaling is promising in translation to a best-in-class treatmen...
Chimeric antigen receptor T-cell therapy (CART) can be administered outpatient yet requires management of potential side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The pre-infusion tumor burden is associated with CRS, yet there...
但细胞因子风暴以及神经毒性依然是CART疗法在最为常见也最为棘手的安全性问题。目前研究人员已经发现了严重CRS和神经毒性的一些危险因素,包括一些预测性的生物标志物,这些生物标志物能够预测患者在CAR-T细胞治疗期间可能经历严重的CRS和神经毒性,从而可以对可能具有毒性的患者进行早期干预管理。当然目前两种毒性的分子机制...
We found that although CD8 CART19 cells are the predominant cytotoxic cells in our assay, CD4 cells were the main driver of IL-6/CRS (Fig 3A). Surface CD40L was expressed rapidly and transiently after activation exclusively in CD4 CART19 (data not shown) and since CD40L can be cleaved ...